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Left ventricular diastolic dysfunction
Background: Albuminuria is an established risk factor for mortality and cardiovascular events in high-risk popu-
lations. However, few studies have evaluated the relationship between normoalbuminuria and left ventricular
(LV) diastolic function. The present study evaluated the impact of the low-grade albuminuria on LV diastolic
function in patients with coronary artery disease (CAD).
Methods:A cross-sectional studywas conducted in 202 chronic CAD patients with normal urinary albumin levels.
Subjects were divided into 3 tertiles according to sex-speciﬁc urinary albumin-to-creatinine concentration ratio
(UACR) cut-off points. Subjects in the upper tertile were classiﬁed as having low-grade albuminuria. To evaluate
the LV function, all subjects underwent echocardiography. LV diastolic dysfunction was deﬁned as E/e′ N 15 or
28 b E/e′ b 15, with an E/A b 0.5, a deceleration time N 280 ms, and a LV mass index N 122 g/m for women or
N149 g/m2 for men.
Results: Among the 202 patients, 76 patients (37.6%) had LV diastolic dysfunction. The prevalence of LV diastolic
dysfunction in the upper tertile was signiﬁcantly greater than that in the middle and lower tertiles (49.3%, 32.3%
and 29.2%, respectively; p for trend = 0.029). Adjusting for confounding factors, the presence of low-grade
albuminuria independently associated with LV diastolic dysfunction (odds ratio 2.22, 95% conﬁdence interval:
1.05–4.71, p = 0.037).
Conclusions: A high UACR level that is still below the current microalbuminuria threshold is signiﬁcantly associ-
ated with an increased prevalence of LV diastolic dysfunction in CAD patients. Our data suggest that low-grade
albuminuria in high-risk populations may provide greater cardiovascular risk stratiﬁcation.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Presence of albuminuria is strongly associated with increased risk of
cardiovascularmorbidity andmortality in the general population [1], as
well as in high-risk populations, which include patients with diabetes
and hypertension [2,3]. Recently, low-grade albuminuria (below
currently deﬁned cutoff point) was also revealed to be associated with
adverse cardiovascular events and could be a predictive factor of
hypertension and metabolic syndrome in general populations [4–6].
The high prevalence of patients with heart failure with a preserved
ejection fraction (HFpEF) has highlighted the important role of left ven-
tricular (LV) diastolic dysfunction in the development of heart failurey, Nagoya University Graduate
466-8550, Japan. Tel.: +81 52
zuki@med.nagoya-u.ac.jp
land Ltd. This is an open access article u(HF) [7,8]. In addition, diastolic dysfunction is associated with poor
prognosis, particularly in patients with advanced HF and a reduced
ejection fraction [9]. Several studies have reported that higher urinary
albumin excretion is associated with higher cardiovascular mortality
in patients with HF [10,11].
However, few studies have evaluated the relationship between
albuminuria below currently deﬁned cutoff points (normoalbuminuria)
and the LV diastolic function in high-risk populations. Therefore, the
aim of this study was to evaluate the impact of low-grade albuminuria
on LV diastolic dysfunction in patients with CAD.
2. Methods
2.1. Study design
This observational study included a total of 202 chronic CADpatients
who were treated with percutaneous coronary intervention at Nagoya
University Hospital between September 2012 and April 2014. Chronicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline patient characteristics.
Variables LV diastolic dysfunction p-Value
Yes (N= 76) No (N= 126)
Demographics
Male, n (%) 49 (64.5) 99 (78.6) 0.033
Age, years 71.4 ± 8.5 67.5 ± 10.3 0.006
BMI, kg/m2 23.3 ± 3.9 23.9 ± 3.7 0.24
Hypertension, n (%) 60 (78.9) 84 (66.7) 0.077
Diabetes, n (%) 36 (47.4) 36 (28.6) 0.010
Dyslipidemia, n (%) 57 (75.0) 99 (78.6) 0.61
Current smoker, n (%) 16 (21.1) 27 (21.4) 0.98
Systolic blood pressure (mm Hg) 127.1 ± 17.7 125.8 ± 17.0 0.61
Diastolic blood pressure (mm Hg) 72.2 ± 11.3 73.1 ± 10.0 0.54
Laboratory data
Hemoglobin (g/dL) 12.9 ± 1.8 13.3 ± 1.8 0.16
LDL-C (mg/dL) 98.1 ± 31.5 97.8 ± 30.1 0.94
HDL-C (mg/dL) 45.7 ± 12.4 45.7 ± 11.3 0.97
Triglycerides (mg/dL) 110 (74–150) 122 (83–167) 0.13
Fasting glucose (mg/dL) 121.0 ± 35.8 111.7 ± 31.1 0.056
Hemoglobin A1C (%) 6.5 ± 0.9 6.2 ± 0.9 0.017
eGFR (mL/min/1.73 m2) 64.8 ± 17.1 71.6 ± 17.5 0.008
UACR (mg/gCr) 10.7 ± 7.3 7.5 ± 5.9 0.001
BNP (pg/dL) 36 (18–103) 19 (10–62) 0.015
Medications
ACE-I or ARB, n (%) 48 (63.2) 74 (58.7) 0.56
Ca channel blocker, n (%) 31 (40.8) 50 (39.7) 0.88
Beta-blocker, n (%) 27 (35.5) 26 (20.6) 0.022
Diuretics, n (%) 12 (15.8) 14 (11.1) 0.39
Data are presented as means ± SD, or as medians (interquartile ranges), or as number
(percentages).
LV, left ventricular; BMI, body mass index; LDL-C, low-density lipoprotein-cholesterol.
HDL-C, high-density lipoprotein-cholesterol; eGFR, estimated glomerular ﬁltration rate.
UACR, urinary albumin to creatinine ratio; BNP, brain natrium peptide.
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotension receptor blocker.
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albuminuria (macro- and micro-), those with a history of myocardial
infarction, those with congestive heart failure, those with moderate to
severe valvular heart disease, and those with LV systolic dysfunction
(deﬁned as an LV ejection fraction less than 50%).
This studywas approved by the research and ethics committees, and
was conducted in accordance with the ethical principles stated by the
1975 Declaration of Helsinki. Written informed consent was obtained
from all patients before any procedures were conducted.
2.2. Laboratory analysis
Blood samples were obtained from all patients after a 12-hour over-
night fast. Urinary albumin excretion was expressed using an albumin-
to-creatinine concentration ratio (ACR), evaluated in a randommorning
urine specimen. Immunoturbidometry (TIA-ALBG, Serotec, Chitose,
Japan) was used to determine urinary albumin concentration, and a
modiﬁed Jaffe method was used to measure urinary creatinine concen-
tration. Albuminuria was deﬁned as a urinary ACR (UACR)≥ 30 μg/mg;
microalbuminuria was deﬁned as UACR in the 30–300 μg/mg range
and macroalbuminuria, as a UACR ≥ 300 μg/mg. Normoalbuminuria
was deﬁned as a UACR b 30 μg/mg [12]. Moreover, patients with
normoalbuminuria were grouped into tertiles on the basis of sex-
speciﬁc UACR distribution. Males with a UACR b 4 μg/mg, 4 μg/mg
≤ UACR b9 μg/mg, or 9 μg/mg ≤ UACR b30 μg/mg were grouped
into tertiles 1, 2 and 3 respectively. Females with a UACR b 3 μg/mg,
3 μg/mg ≤ UACR b10 μg/mg, or 10 μg/mg ≤ UACR b30 μg/mg were
grouped into tertiles 1, 2 and 3 respectively. Subjects in the highest
UACR tertile were deﬁned as having low-grade albuminuria.
2.3. Echocardiography
Standard M-mode and 2-dimensional echocardiography, Doppler
blood ﬂow, and tissue Doppler imagingmeasurements were performed
in concordance with the American Society of Echocardiography
guidelines [13], using the Vivid 7 system (GE Healthcare, Milwaukee,
WI, USA). LV end-diastolic volume and end-systolic volume were
measured using Simpson's biplane method to calculate LV ejection
fraction. Mitral inﬂow velocities were recorded using pulsed-wave
Doppler echocardiography in the apical 4-chamber view. The early
(E) and late (A) transmitral diastolic velocities and deceleration time
weremeasured at the leaﬂet tips. The ratio of Ewave to the early diastol-
icmitral annular velocity (E/e′)was determined using color-coded tissue
Doppler imagingwith the sample volume positioned in the septal mitral
annulus. LV diastolic dysfunction was deﬁned in line with the ﬁndings
from a previous report [14]. Brieﬂy, electrocardiographic evidence of
atrial ﬁbrillation or an E/e′ N 15 or 8 b E/e′ b 15, with an E/A b 0.5, a
deceleration time N 280 ms, and an LV mass index N 122 g/m2 for
women or N149 g/m2 for men deﬁned LV diastolic dysfunction.
2.4. Deﬁnitions
Hypertension was deﬁned as systolic blood pressure ≥ 140 mmHg,
diastolic blood pressure ≥ 90 mm Hg and/or current antihypertensive
medication use. Diabetes mellitus was deﬁned as the use of any
antihyperglycemic medication, a current diagnosis of diabetes or a
fasting plasma glucose concentration N 126mg/dL and/or a glycosylated
hemoglobin concentration ≥ 6.5% (National Glycohemoglobin
Standardization Program). Dyslipidemia was deﬁned as low-density
lipoprotein cholesterol ≥ 140 mg/dL, high-density lipoprotein (HDL)
cholesterol b 40 mg/dL, triglycerides ≥ 150 mg/dL, and/or administra-
tion of lipid-lowering therapy. Smoking habit was deﬁned as a current
habit or discontinued cigarette use≤ 6months before PCI. The estimated
glomerular ﬁltration rate (eGFR) was calculated according to a new
equation developed in Japan: eGFR (mL/min/1.73 m2) = 194 × serum
creatinine− 1.094 × age− 0.287 × 0.739 (in females) [15].2.5. Statistical analysis
Continuous variables were expressed as means ± standard
deviations or median (interquartile range) if they were non-normally
distributed. Categorical variables were expressed as percentages. The
Student's t-test was used to statistically analyze normally distributed
data (continuous variables), and the chi-squared test or Fisher's exact
test was used to statistically analyze categorical data. To identify inde-
pendent predictors of LV diastolic dysfunction, multivariate logistic
regression analysis was performed for traditional cardiovascular risk
factors. A 2-sided p-value b 0.05 was considered to indicate statistical
signiﬁcance. SPSS version 18.0 for Windows (SPSS, Inc., Chicago, IL,
USA) was used to perform all statistical analyses.3. Results
Among the 202 patients, 76 patients in the study population (37.6%)
had LV diastolic dysfunction. Patient characteristics and echocardio-
graphic ﬁndings are listed in Table 1 and Table 2, respectively. There
were signiﬁcant differences in age, number of males, eGFR levels,
UACR, and in the prevalence of hypertension and diabetes between
the 2 groups. The prevalence of beta-blocker use and diuretic use
tended to be higher in patients with LV diastolic dysfunction compared
to those without.
The prevalence of LV diastolic dysfunction in tertile 3 (low-grade al-
buminuria) was higher than the prevalence observed in tertile 2 and
tertile 1 (49.3%, 32.3% and 29.2%, respectively; p for trend = 0.029,
Fig. 1). Table 3 shows the results of multivariate logistic analysis that
investigated the relationship between LV diastolic dysfunction and
age, sex, body mass index, hypertension, diabetes mellitus, UACR and
eGFR levels in all subjects. Low-grade albuminuria independently
associated with LV diastolic dysfunction after adjustment for these con-
founding factors (odds ratio 2.22, 95% conﬁdence interval: 1.05–4.71,
Table 2
Echocardiographic ﬁndings.
Variables LV diastolic dysfunction p-Value
Yes (N= 76) No (N= 126)
Left atrial dimension (mm) 38.7 ± 6.8 35.2 ± 5.5 b0.001
Interventricular septum thickness (mm) 9.4 ± 1.8 9.0 ± 1.6 0.13
LV posterior wall thickness (mm) 9.7 ± 1.8 9.0 ± 1.5 0.005
LV diastolic dimension (mm) 49.1 ± 5.8 47.0 ± 5.5 0.012
LV systolic dimension (mm) 31.2 ± 5.5 30.0 ± 5.3 0.15
LV ejection fraction (%) 65.7 ± 8.9 65.7 ± 7.4 0.98
LV mass index, g/m2 128.1 ± 36.8 105.3 ± 23.1 b0.001
Peak E-wave velocity (cm/s) 78.2 ± 21.8 62.9 ± 13.8 b0.001
Peak A-wave velocity (cm/s) 89.9 ± 27.4 82.7 ± 17.4 0.027
E-wave/A-wave ratio 0.92 ± 0.40 0.79 ± 0.22 0.004
Deceleration time (ms) 227.9 ± 62.5 239.7 ± 60.6 0.19
Septal e′ (cm/s) 4.8 ± 1.4 6.0 ± 1.5 b0.001
E-wave/septal e′ 17.3 ± 6.0 10.7 ± 2.5 b0.001
Data are presented as mean ± SD, LV, left ventricular.
Table 3
Multiple logistic regression analysis for left ventricular diastolic dysfunction.
Variables Simple regression Multiple regression
OR 95% CI p-Value OR 95% CI p-Value
Male gender 0.50 0.26–0.93 0.030 0.53 0.26–1.10 0.087
Age (years) 1.06 1.01–1.08 0.007 1.03 0.99–1.07 0.17
BMI, kg/m2 0.96 0.88–1.03 0.24
Current smoker 0.95 0.47–1.90 0.88
Hypertension 1.88 0.97–3.64 0.064 1.55 0.76–3.18 0.23
Systolic BP (mm Hg) 1.01 0.98–1.02 0.54
Diastolic BP (mm Hg) 0.96 0.97–1.02 0.24
Diabetes 2.25 1.24–4.07 0.007 2.56 1.35–4.92 0.004
Hemoglobin (g/dL) 0.89 0.76–1.05 0.16
LDL-C (mg/dL) 1.00 0.99–1.01 0.94
HDL-C (mg/dL) 1.00 0.98–1.02 0.97
eGFR (mL/min/1.73 m2) 0.98 0.96–0.99 0.009 0.98 0.96–1.00 0.037
UACR
Tertile 1 1.00 (reference) 1.00 (reference)
Tertile 2 1.15 0.54–2.45 0.71 1.21 0.53–2.76 0.64
Tertile 3 2.36 1.17–4.75 0.016 2.22 1.05–4.71 0.037
Multivariate model includes all variables at baseline with p b 0.10 by univariate analysis.
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; BP, blood pressure.
LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol.
eGFR, estimated glomerular ﬁltration rate; UACR, urinary albumin to creatinine ratio.
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independent predictors for LV diastolic dysfunction.
4. Discussion
The main ﬁnding of the present study was that low-grade albumin-
uria, which notably had a UACR less than the current microalbuminuria
threshold of 30 μg/mg, associated with LV diastolic dysfunction in CAD
patients independent of other cardiovascular risk factors. Our data
suggest that low-grade albuminuria in high-risk populations may
provide greater cardiovascular risk stratiﬁcation.
Several recent studies have focused on the association between low-
grade albuminuria and cardiovascular risk factors. In a community-based
sample of non-hypertensive and non-diabetic individuals, low-grade
albuminuria predicted the development of cardiovascular disease such
as hypertension and metabolic syndrome [5,6]. Moreover, the Heart
Outcomes Prevention Evaluation (HOPE) study indicated that there
was no evident UACR threshold and that UACR increased the risk of
cardiovascular disease in a continuous manner [16]. In this study, every
3.01 mg/g increment in UACR conferred a 5.9% increase in major cardio-
vascular events. The study suggested that elevated UACR within the
normal range (under the microalbuminuria threshold of 30 μg/mg)
signiﬁcantly associated with the increasing prevalence of myocardial
dysfunction. Low-grade albuminuria also independently associatedFig. 1. The prevalence of left ventricular diastolic dysfunction in tertile 3 (low-grade
albuminuria) was signiﬁcantly greater than that in tertile 2 and tertile 1 (49.3%, 32.3%
and 29.2%, respectively; p for trend = 0.029).with LV diastolic dysfunction; cutoff values used in this analysis were
almost identical with the thresholds deﬁned in large-cohort study as
being indicative of cardiovascular mortality risk [16,17].
Although the pathophysiologicmechanismsunderlying albuminuria
in patients with HFpEF remain uncertain, several pathophysiologic
mechanisms have been proposed. One suggestion is that albuminuria
is related to various inﬂammatory markers [18,19]. A systemic inﬂam-
matory state affects the coronary microvascular endothelium. Coronary
microvascular endothelial inﬂammation, in turn, reduces myocardial
nitric oxide (NO) bioavailability, which results in lower protein kinase
G (PKG) activity. Declining PKG activity subsequently accelerates pro-
hypertrophic signaling and increases myocyte stiffness, enhancing LV
diastolic dysfunction and ventricular stiffening [20]. A second explana-
tion is that albuminuria may be an early sign of renal damage. Although
kidney function remains clinically stable, a reduced number of nephrons
and hyperﬁltration could lead to albuminuria [21]. This will lead to
compensatory mechanisms, such as activation of the renin–angiotensin
system and increased sympathetic activity, which could subsequently
affect the cardiovascular system. This is supported by a previous report
that has shown a deﬁnite link between pulmonary capillary hyperten-
sion and renal damage [22]. Thus, the presence of low-grade albuminuria
might reﬂect early renal damage and pulmonary capillary hypertension.
5. Study limitations
The present study had several limitations. First, this was a single-
center study involving a relatively small number of patients. Second,
EAE/ASE guideline is recommended as the evaluation of the LV dia-
stolic function recently [23]. However we did not measure the e′ of
lateral mitral annulus in all patients, we could not follow this most
standard guideline regrettably. Serial changes in the amount of
urine albumin, were therefore, not investigated. Finally, the impact
of other medical conditions on albuminuria, such as the duration
of diabetes mellitus and status of blood glucose levels, was not
assessed.
6. Conclusion
Our data suggests that albuminuria, even at low levels, is associated
with LV diastolic dysfunction. These ﬁndings highlight a group of
asymptomatic individuals who may be at increased risk for overt
myocardial dysfunction and progression to HF. HF has a poor prognosis
and still remains a major cause of death and hospitalization. The
16 H. Nagai et al. / IJC Metabolic & Endocrine 6 (2015) 13–16identiﬁcation of patients at a greater risk of developing HF is critical for
the timely utilization of appropriate prevention strategies. Thus, it is
important to consider treatments to reduce albuminuria in order to
improve clinical outcomes. Furthermore, as the clinical measurement
of UACR is simple and can be repeated multiple times, this procedure
may be of value in the risk stratiﬁcation of patients in high-risk
populations.Disclosure
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